Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1264  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2633    
    Printed92    
    Emailed0    
    PDF Downloaded118    
    Comments [Add]    

Recommend this journal

 

 NI FEATURE: THE QUEST - COMMENTARY
Year : 2016  |  Volume : 64  |  Issue : 6  |  Page : 1266--1275

Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug


1 Department of PhD, PhD Program in Biological and Health Sciences, Universidad Autonoma Metropolitana Iztapalapa-Xochimilco-Cuajimalpa, México, Calzada del Hueso 1100, Col. Villa Quietud, México, D.F. 04960, Mexico
2 Department of Neurosciences, Instituto Nacional de Rehabilitación, “Luis Guillermo Ibarra Ibarra”, Secretaría de Salud, Col. Arenal de Guadalupe, México, D.F. 14389, Mexico
3 Department of Reproductive Biology, Universidad Autónoma Metropolitana Campus Iztapalapa, México, D.F. 09340, Mexico
4 Department of Cell and Tissue Morphology, Instituto Nacional de Pediatria, Col. Insurgentes Sur 3700-C, México, D. F. 04530, Mexico

Correspondence Address:
Dr. A Alfaro-Rodríguez
Neurofarmacology, Department of Neurosciences, Instituto Nacional de Rehabilitacion, “Luis Guillermo Ibarra Ibarra”. Calzada Mexico-Xochimilco 289, Col. Arenal de Guadalupe, Mexico, D.F. 14389
Mexico
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.193801

Rights and Permissions

The main purpose of this review was to expound upon the mechanism of action of Levetiracetam (LEV) as an antiepileptic, neuroprotective, and hyperalgesic drug. LEV is a second-generation anti-epileptic drug (AED) that is approved for clinical use as monotherapy and may also be used for adjunctive treatment of patients with seizures. Several researchers have recommended LEV as a treatment option in different diseases causing neuronal damage, and recently, LEV has been used as an antihyperalgesic drug. LEV exhibits favorable characteristics, including a low potential for interaction, a short elimination half-life, and has neither active metabolites nor major negative effects on cognition. This has generated many new research avenues for the utilization of this drug. However, the precise mechanism of action of LEV has not been fully elucidated. In this review, a search was conducted on PubMed, ProQuest, EBSCO, and the Science Citation index for studies evaluating the effects of LEV as an antiepileptic, neuroprotective, and hyperalgesic drug. A total of 32 studies related to the use of LEV suggested different mechanisms of action, such as binding to the synaptic vesicle glycoprotein 2A (SV2A) protein, inhibition of Ca2+ N-type channels, and its presence as a neuromodulator. These studies concluded that the pharmacodynamics of LEV should be viewed as a single pathway, and should not be based on specific molecular targets that depend on the physiological or pathological conditions prevalent at that time.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow